Cody J Peer1, Jung-Min Lee2, Jeffrey Roth1, Louis Rodgers1, Jeffers Nguyen1, Christina M Annunziata2, Lori Minasian3, Elise C Kohn2, William D Figg4. 1. Clinical Pharmacology Program, CCR, National Cancer Institute, NIH, 9000 Rockville Pike, Building 10, Room 5A01, Bethesda, MD, 20892, USA. 2. Women's Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD, 20892, USA. 3. Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, MD, 20892, USA. 4. Clinical Pharmacology Program, CCR, National Cancer Institute, NIH, 9000 Rockville Pike, Building 10, Room 5A01, Bethesda, MD, 20892, USA. wf13e@nih.gov.
Abstract
PURPOSE: Combining olaparib with carboplatin was recently shown to be active in both BRCA and non-BRCA mutant cancers in a recent phase I/Ib combination trial. The optimal drug sequence recommended was carboplatin 1-day before olaparib. However, carboplatin pre-treatment induced a ~50% faster olaparib clearance. METHODS: To further explore this drug interaction, a population pharmacokinetic (PK) model was designed that included a lag time parameter, a second absorption compartment from tablet formulation, a single distribution/elimination compartment, and covariance among the clearance and volume parameters. RESULTS: Clearance (6.8 L/h) and volume (33 L) estimates were comparable with literature. The only significant covariate was the presence of carboplatin on olaparib clearance, consistent with published noncompartmental PK and in vitro data. CONCLUSIONS: Simulations predicted lower steady-state peak/trough olaparib exposure through 24-36 h post carboplatin pre-treatment, but this effect was lost by day 2 and thus no dose adjustment is recommended.
PURPOSE: Combining olaparib with carboplatin was recently shown to be active in both BRCA and non-BRCA mutant cancers in a recent phase I/Ib combination trial. The optimal drug sequence recommended was carboplatin 1-day before olaparib. However, carboplatin pre-treatment induced a ~50% faster olaparib clearance. METHODS: To further explore this drug interaction, a population pharmacokinetic (PK) model was designed that included a lag time parameter, a second absorption compartment from tablet formulation, a single distribution/elimination compartment, and covariance among the clearance and volume parameters. RESULTS: Clearance (6.8 L/h) and volume (33 L) estimates were comparable with literature. The only significant covariate was the presence of carboplatin on olaparib clearance, consistent with published noncompartmental PK and in vitro data. CONCLUSIONS: Simulations predicted lower steady-state peak/trough olaparib exposure through 24-36 h post carboplatin pre-treatment, but this effect was lost by day 2 and thus no dose adjustment is recommended.
Entities:
Keywords:
Carboplatin; Drug interaction; Olaparib; Population pharmacokinetics
Authors: Stan B Kaye; Jan Lubinski; Ursula Matulonis; Joo Ern Ang; Charlie Gourley; Beth Y Karlan; Amit Amnon; Katherine M Bell-McGuinn; Lee-May Chen; Michael Friedlander; Tamar Safra; Ignace Vergote; Mark Wickens; Elizabeth S Lowe; James Carmichael; Bella Kaufman Journal: J Clin Oncol Date: 2011-12-27 Impact factor: 44.544
Authors: Karen A Gelmon; Marc Tischkowitz; Helen Mackay; Kenneth Swenerton; André Robidoux; Katia Tonkin; Hal Hirte; David Huntsman; Mark Clemons; Blake Gilks; Rinat Yerushalmi; Euan Macpherson; James Carmichael; Amit Oza Journal: Lancet Oncol Date: 2011-08-19 Impact factor: 41.316
Authors: M William Audeh; James Carmichael; Richard T Penson; Michael Friedlander; Bethan Powell; Katherine M Bell-McGuinn; Clare Scott; Jeffrey N Weitzel; Ana Oaknin; Niklas Loman; Karen Lu; Rita K Schmutzler; Ursula Matulonis; Mark Wickens; Andrew Tutt Journal: Lancet Date: 2010-07-06 Impact factor: 79.321
Authors: Andrew Tutt; Mark Robson; Judy E Garber; Susan M Domchek; M William Audeh; Jeffrey N Weitzel; Michael Friedlander; Banu Arun; Niklas Loman; Rita K Schmutzler; Andrew Wardley; Gillian Mitchell; Helena Earl; Mark Wickens; James Carmichael Journal: Lancet Date: 2010-07-06 Impact factor: 79.321
Authors: Peter C Fong; Timothy A Yap; David S Boss; Craig P Carden; Marja Mergui-Roelvink; Charlie Gourley; Jacques De Greve; Jan Lubinski; Susan Shanley; Christina Messiou; Roger A'Hern; Andrew Tutt; Alan Ashworth; John Stone; James Carmichael; Jan H M Schellens; Johann S de Bono; Stan B Kaye Journal: J Clin Oncol Date: 2010-04-20 Impact factor: 44.544
Authors: Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono Journal: N Engl J Med Date: 2009-06-24 Impact factor: 91.245
Authors: Andres Poveda; Ana Oaknin; Ignacio Romero; Angel Guerrero-Zotano; Lorena Fariñas-Madrid; Victor Rodriguez-Freixinos; Pedro Mallol; Raquel Lopez-Reig; Jose Antonio Lopez-Guerrero Journal: Sci Rep Date: 2021-02-24 Impact factor: 4.379